Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) ...

The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...

Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making.

A fast-acting powder turns blood into a sealing gel, stopping life-threatening bleeding where pressure and patches often fail ...

Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory ...

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

Breye Therapeutics has reported promising early clinical findings for its lead oral therapy danegaptide, following a presentation at the Angiogenesis, Exudation and Degeneration 2026 symposium.

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, ...

Danish clinical-stage retinal diseases biotech Breye Therapeutics today announced clinical data showcasing the potential of its lead candidate, danegaptide.

Announcing a new article publication for BIO Integration journal. Cardiac cell death and myocardial fibrosis after ischemia-reperfusion (I/R) injury are the primary causes of impaired cardiac function ...

Breye is advancing danegaptide to Phase II trials after the drug showed signs of improving disease activity in a Phase Ib study.

LL-37 continues to attract scientific interest due to its unique structural characteristics and its diverse interactions within biological systems. As the only known cathelicidin-derived peptide, LL-3 ...